New Blood Test to Diagnose and Predict Outcomes in Liposarcoma Patients Using Serine Levels

What this Trial Is About

Liposarcoma LPS, the most common type of soft tissue sarcoma, is a rare cancer affecting adults. This research aims to identify a new non-invasive blood test by measuring circulating serine levels to help diagnose and predict the prognosis of well-differentiated and dedifferentiated liposarcomas. Currently, diagnosis relies on detecting Mdm2 gene amplification through a biopsy-based method called FISH, which has limitations such as invasiveness and insufficient representation of tumor diversity. The study involves collecting blood samples from both healthy volunteers and LPS patients. Healthy subjects will provide a single blood sample, while patients will have multiple samples taken one before surgery, a second about 4 weeks after surgery, and then every 3 months for 18 months. The blood test uses advanced chromatography and mass spectrometry techniques to measure amino acids, including serine, which may reflect tumor presence and activity. Participants will undergo scheduled blood draws and clinical monitoring throughout the study. Researchers will analyze serine levels to assess their accuracy in diagnosing LPS and predicting relapse after surgery. The main outcome is the sensitivity and specificity of serine measurement at 3 months post-surgery, with additional follow-up for relapse-free survival and serine level changes over 18 months. The study is designed to be patient-friendly, aiming to improve diagnosis and prognosis without invasive biopsies.

Identification of a New Blood Biomarker for the Diagnosis and Prognosis of Liposarcomas